1. Home
  2. GPMT vs SKYE Comparison

GPMT vs SKYE Comparison

Compare GPMT & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GPMT
  • SKYE
  • Stock Information
  • Founded
  • GPMT 2015
  • SKYE 2012
  • Country
  • GPMT United States
  • SKYE United States
  • Employees
  • GPMT N/A
  • SKYE N/A
  • Industry
  • GPMT Real Estate Investment Trusts
  • SKYE Biotechnology: Pharmaceutical Preparations
  • Sector
  • GPMT Real Estate
  • SKYE Health Care
  • Exchange
  • GPMT Nasdaq
  • SKYE Nasdaq
  • Market Cap
  • GPMT 122.0M
  • SKYE 108.5M
  • IPO Year
  • GPMT 2017
  • SKYE N/A
  • Fundamental
  • Price
  • GPMT $3.01
  • SKYE $3.91
  • Analyst Decision
  • GPMT Buy
  • SKYE Buy
  • Analyst Count
  • GPMT 3
  • SKYE 7
  • Target Price
  • GPMT $3.13
  • SKYE $15.50
  • AVG Volume (30 Days)
  • GPMT 206.4K
  • SKYE 314.0K
  • Earning Date
  • GPMT 11-05-2025
  • SKYE 11-06-2025
  • Dividend Yield
  • GPMT 6.60%
  • SKYE N/A
  • EPS Growth
  • GPMT N/A
  • SKYE N/A
  • EPS
  • GPMT N/A
  • SKYE N/A
  • Revenue
  • GPMT N/A
  • SKYE N/A
  • Revenue This Year
  • GPMT N/A
  • SKYE N/A
  • Revenue Next Year
  • GPMT $26.51
  • SKYE N/A
  • P/E Ratio
  • GPMT N/A
  • SKYE N/A
  • Revenue Growth
  • GPMT N/A
  • SKYE N/A
  • 52 Week Low
  • GPMT $1.61
  • SKYE $1.14
  • 52 Week High
  • GPMT $3.66
  • SKYE $6.01
  • Technical
  • Relative Strength Index (RSI)
  • GPMT 61.50
  • SKYE 54.00
  • Support Level
  • GPMT $2.93
  • SKYE $3.71
  • Resistance Level
  • GPMT $3.08
  • SKYE $4.55
  • Average True Range (ATR)
  • GPMT 0.07
  • SKYE 0.31
  • MACD
  • GPMT -0.00
  • SKYE 0.02
  • Stochastic Oscillator
  • GPMT 72.41
  • SKYE 49.61

About GPMT Granite Point Mortgage Trust Inc.

Granite Point Mortgage Trust Inc focuses on directly originating, investing in, and managing senior floating rate commercial mortgage loans and other debt and debt-like commercial real estate investments. The company constructs its investment portfolio on a loan-by-loan basis, emphasizing rigorous credit underwriting, selectivity, and diversification, and assesses each investment from a fundamental value perspective relative to other opportunities available in the market. It typically provides intermediate-term bridge or transitional financing for a variety of purposes, including acquisitions, recapitalizations, refinancing, and a range of business plans, including lease-up, renovation, repositioning and repurposing of the property.

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: